Bortezomib

Bortezomib, or Velcade, blocks an internal waste-dispensing mechanism for proteins that is particularly hyperactive in cancer cells.

The Emperor of All Maladies Siddhartha Mukherjee 2010

Bortezomib, or Velcade, blocks an internal waste-dispensing mechanism for proteins that is particularly hyperactive in cancer cells.

The Emperor of All Maladies Siddhartha Mukherjee 2010

Bortezomib, or Velcade, blocks an internal waste-dispensing mechanism for proteins that is particularly hyperactive in cancer cells.

The Emperor of All Maladies Siddhartha Mukherjee 2010

In multiple myeloma MM patients, it generated promising data in a phase I/II trial when given in combination with Bortezomib [16] and the results prompted its use in phase II studies in MM [17] where it showed notable efficacy.

unknown title 2011

Bortezomib can improve control of GVHD and immune system recovery

THE MEDICAL NEWS Editors 2010

Bortezomib is a member of a class of drugs called proteasome inhibitors, which decreases the effectiveness of enzymes that cells use to dispose of non-functioning proteins.

Scientific Blogging 2010

Phase I-II trials combining two or more novel agents targeting the bone marrow microenvironment, such as Lenalidomide and Bortezomib, have shown significant higher response rates, lower drug resistance and fewer side effects in myeloma patients, according to Dr. Anderson.

WN.com - Articles related to Physicians in Qatar work on treatment of ovarian cancer 2010

Bortezomib can improve control of GVHD and immune system recovery

THE MEDICAL NEWS 2010

Phase I-II trials combining two or more novel agents targeting the bone marrow microenvironment, such as Lenalidomide and Bortezomib, have shown significant higher response rates, lower drug resistance and fewer side effects in myeloma patients, according to Dr. Anderson.

WN.com - Articles related to Physicians in Qatar work on treatment of ovarian cancer 2010

Bortezomib can improve control of GVHD and immune system recovery

THE MEDICAL NEWS Editors 2010